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Cross-sectional studies on the correlation between serum hepatitis C virus (HCV) RNA and 
alanine aminotransferase (ALT) levels in patients with chronic hepatitis C have yielded 
conflicting results. We conducted a longitudinal study to examine the correlation between 
HCV viremia and serum ALT levels in individual patients over time. Serial samples (mean 9) 
from 25 patients with chronic HCV infection, including interferon-treated and untreated 
immunocompetent and immunosuppressed patients, collected over a period of 1-4.8 years 
(mean 2.6 years) were tested for HCV RNA and ALT levels using a highly reproducible 
quantitative (bDNA) assay. A significant correlation was found between serum HCV RNA 
and ALT levels in the patients who received IFN therapy, but no correlation was observed in 
the untreated patients. Among the untreated patients, the immunosuppressed patients had 
significantly higher HCV RNA levels (39 _+ 4 vs 3.6 _ 8 Meq/ml, P < 0.0001) but significantly 
lower ALT (56 ___ 11 vs 97 _ 12 units/liter, P = 0.03) levels when compared to the 
immunocompetent ones. In summary, we found no correlation between serum HCV RNA 
and ALT levels in chronic hepatitis C patients who are not receiving interferon therapy. 
Immunosuppression results in higher HCV RNA but lower ALT levels. 
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The pathogenesis of hepatitis C virus (HCV) 
-induced liver injury remains unresolved. Early stud- 
ies suggested that HCV may be a cytopathic virus. 
This is supported by reports that patients with more 
active or advanced liver disease have higher levels of 
viremia (1-8). In addition, among patients who re- 
ceive interferon therapy, a decrease in serum amino- 
transferase (ALT) levels during treatment is usually 
accompanied by a parallel fall in serum HCV RNA 
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levels, and a relapse in ALT levels after treatment is 
accompanied by reappearance of HCV RNA in se- 
rum (9-14). However, recent studies found that while 
immunosuppressive therapy increases serum HCV 
RNA levels, ALT levels are decreased, suggesting 
that HCV-induced liver injury is immune-mediated 
(15-18). Other evidence in support of immune- 
mediated liver injury in chronic hepatitis C is the 
frequent presence of lymphoid aggregates in the por- 
tal tracts which contain activated B as well as T cells 
(19, 20) and the recent demonstration of cytotoxic T 
lymphocytes that react against HCV antigens in liver 
biopsies (21-27). Furthermore, some studies found 
no correlation between serum HCV RNA levels and 
biochemical/histological activity of liver disease (2, 
4-7, 28). 
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Several factors contr ibute  to the discrepant  reports  
on the correlat ion between serum H C V  R N A  and 
A L T  levels. Most  repor ts  were  based  on cross-  
sectional studies. It is possible that  the relationship 
between serum H C V  R N A  and A L T  levels may differ 
in different patients depending  on the stage of  liver 
disease and immune  response o f  the host. More  
meaningful  data  may be genera ted  by studying serial 
samples f rom the same patients.  While there are 
many reports  on the effects of  interferon therapy on 
changes  in serum A L T  and H C V  R N A  levels, very 
few longitudinal studies have been pe r fo rmed  on 
unt rea ted  patients (1, 28). Most  of  the latter studies 
employed  assays [such as end-point  dilution polymer-  
ase chain react ion (PCR)  assay] that have marked  
interassay variability and are at best semiquantitat ive.  
Owing to the laborious nature of  these assays, very 
few samples at scat tered time points were tested for 
serum H C V  R N A  levels. Thus,  accurate correlat ion 
between serum H C V  R N A  and A L T  levels cannot  be 
determined.  
The  aim of  this study was to reexamine the corre-  
lation between the level of  hepatitis C viremia and 
activity o f  liver disease (as de termined  by A L T  level) 
in patients with chronic  H C V  infection by testing 
multiple serum samples using a highly reproducible ,  
quanti tat ive H C V  R N A  assay (bDNA) .  To de te rmine  
whe ther  the relationship between serum H C V  R N A  
and A L T  levels is affected by antiviral and immuno-  
suppressive therapy, three groups  o f  patients were 
studied: un t rea ted  and in terferon- t reated immuno-  
compe ten t  patients and renal t ransplant  recipients 
who received immunosuppress ive  therapy. 
M A T E R I A L S  AND METHODS 
Patients. Twenty-five patients (14 men and 11 women), 
age 23-74 years (mean --_ SEM 44 _ 3 years) with chronic 
HCV infection, who attended the Hepatitis Clinic and the 
Renal Transplant Clinic in Queen Mary Hospital, Hong 
Kong, were studied. All patients were anti-HCV positive by 
second-generation enzyme immunoassays (EIA-2). They 
included 13 immunocompetent patients and 12 renal trans- 
plant recipients. The risk factors for HCV infection were: 
transfusions in 20 (including eight who had hemodialysis), 
occupational exposure in one, and unknown in four (Table 
1). HCV genotyping data was available in 19 patients show- 
ing genotypes lb in 14, 2b in one, 3a in one, and 6a in three. 
Eighteen patients had liver biopsies which showed: minimal 
changes in five, chronic persistent hepatitis in two, chronic 
active hepatitis in nine, and cirrhosis in two (Table 1). 
Among the immunocompetent patients, five received inter- 
feron-a2b therapy, all had elevated ALT levels and liver 
biopsies showing chronic hepatitis prior to initiation of 
treatment. Four patients received 3 MU doses of interferon 
TABLE 1. CHARACTERISTICS OF PATIENTS AT PRESENTATION* 
Immunocompetent 
hnmunosuppressed 
Treated Untreated renal transplant 
Patients (N) 5 8 12 
Age (yr), mean +-- 
SEM 34 --+ 3 55 ----- 5 40 ----. 3 
Sex m/f 2/3 4/4 8/4 
Risk factors 
Blood transfusion 4 4 4 
Occupational 1 0 0 
Transfusion + HD 0 0 8 
Genotype 
lb 3 3 8 
2b 1 0 0 
3a 1 0 0 
6 0 l 2 
N/A 0 4 2 
Liver histology 
Minimal change 0 0 5 
CPH 1 0 1 
CAH 4 2 3 
Cirrhosis 0 2 0 
N/A 0 4 3 
* HD, Hemodialysis; N/A, not available; CPH, chronic persistent 
hepatitis; CAH, chronic active hepatitis. 
thrice weekly for six months, the other patient received 3- to 
5-MU doses for 12 months. Initial response was defined as 
normalization in ALT levels at the end of treatment and 
sustained response as normalization in ALT levels that was 
maintained for at least six months after treatment. All the 
renal transplant recipients were anti-HCV-positive prior to 
transplant, and all received triple immunosuppressive ther- 
apy: prednisone, azathioprine, and cyclosporine. All pa- 
tients were negative for hepatitis B surface antigen 
(HBsAg) and antibody to human immunodeficiency virus 
(anti-HIV) and had no other causes of liver disease. 
Methods. Between 1990 and 1994, an aliquot of serum 
was collected from all anti-HCV-positive patients at each 
clinic visit (every one to six months) and stored at -70°C 
for HCV RNA and genotype assays. Serial samples, 5-13 
(mean 9 __+ 0.5), from each patient collected over a period of 
1-4.8 years (mean 2.6 _+ 0.2 years) were studied. Anti-HCV 
was tested by EIA-2; HBsAg and anti-HIV were tested by 
EIA (Abbott Laboratories, North Chicago, Illinois). Serum 
HCV RNA was detected by a nested reverse transcription- 
PCR (RT-PCR) assay as described previously (29) and 
quantitated by the branched-chain DNA assay (Quantiplex 
bDNA assay, Chiron Corp., Emeryville, California). The 
detection limit of the assay is 3.5 x 105 viral equivalents per 
milliliter of serum (0.35 Meq/ml). HCV genotyping was 
performed using a modification of the Okamoto PCR- 
based typing assay that can differentiate genotypes la, lb, 
2a, 2b, and 3a (30). Additional primers were incorporated 
to identify genotype 6a, which is the second most prevalent 
HCV genotype in Hong Kong (31). 
Statistical Analyses. An arbitrary value of 0.175 Meq/ml 
was assigned to serum samples that were undetectable for 
HCV RNA in the bDNA assay. All analyses on serum HCV 
RNA levels were performed using logarithmically trans- 
formed values. Pearson's test was used to analyze the cor- 
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relation between serum HCV RNA and ALT levels. An 
additional correlation coefficient was calculated for each 
individual patient by comparing all the paired serum HCV 
RNA and ALT levels for that patient. In the interferon 
treated patients, a separate correlation coefficient was cal- 
culated for the period from one month before treatment to 
one month after treatment. Variations in serum HCV RNA 
and ALT levels during the course of follow-up were calcu- 
lated by determining the ratio of the peak versus trough 
HCV RNA and ALT levels for each individual patient. 
Comparisons between groups were performed using the 
Mann-Whitney test. 
RESULTS 
Interferon-Treated Patients (N = 5). All five pa- 
tients were HCV RNA-positive by RT-PCR, and four 
(80%) had detectable HCV RNA by the bDNA assay 
prior to treatment. Initial and sustained response was 
achieved in four and one patients, respectively. Par- 
allel changes in serum HCV RNA and ALT levels 
were observed during treatment in the four patients 
who had detectable HCV RNA by the bDNA assay at 
the onset of treatment (Figure 1). There  was a signif- 
icant correlation between serum HCV RNA and ALT 
levels, especially during the treatment period. The 
mean correlation coefficients and P values for the 
entire observation period were 0.6 and 0.13 and for 
the treatment period were 0.91 and 0.02, respectively. 
All four responders  became serum HCV RNA- 
negative at the end of treatment, but only the sus- 
tained responder remained HCV RNA-negative dur- 
ing posttreatment follow-up. 
U n t r e a t e d  P a t i e n t s  (N = 20). Of  the 20 untreated 
patients, 12 (three immunocompetent  and nine renal 
transplant patients) were persistently serum HCV 
RNA-positive by the bDNA assay. Serum HCV RNA 
was intermittently undetectable in four immunocom- 
petent and three renal transplant patients. Serum 
HCV RN A  was persistently undetectable by the 
bDNA assay in one immunocompetent  patient, al- 
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though he was HCV RNA-positive by RT-PCR. No 
correlation between serum HCV RNA and ALT lev- 
els was observed in any of the 20 untreated patients 
(Figure 2). The correlation coefficients varied from 
0.07 to 0.83 and the P values ranged from 0.06 to 0.97. 
Compared to the immunocompetent patients, the 
renal transplant recipients were similar in age: 40 +- 3 
vs 55 --+ 5 years and had a similar prevalence of HCV 
genotype lb: 8 of 10 vs 3 of 4 (Table 1). Despite 
significantly higher mean serum HCV RNA levels 
[39 _+ 4 vs 3.6 _+ 0.8 Meq/ml (P < 0.0001)], the renal 
transplant recipients had significantly lower mean 
ALT levels: 56 _+ 11 vs 97 _ 12 units/liter (P = 0.03) 
(Table 2) and milder histological liver disease: five of 
nine had minimal changes versus none of four among 
immunocompetent patients (NS). The renal trans- 
plant recipients had fivefold greater variations in se- 
rum HCV RNA levels: 43 _+ 20 vs 8 -+ 2 but a similar 
degree of variation in ALT levels: 5 - 1 vs 4 --- 1 
(Table 2). 
TABLE 2. COMPARISON BETWEEN SERUM HEW RNA AND ALT LEVELS IN UNTREATED 
IMMUNOCOMPETENT ( I f )  AND RENAL TRANSPLANT (RT) PATIENTS* 
Untreated patients 
lrnmunocompetent Renal transplant P 
Patients (N) 
Points evaluated (N) 
Duration of  follow-up (mo) 
Mean ALT (units/liter) 
Variation in ALT during follow-up 
HCV RNA Level (eq/liter × 106) 




22 +-- 2 (13-32) 
97 - 12 (47-143) 
4 +- 1 (1.5--4.8) 
3.6 -+ 0.8 (0.175-39.55) 
8 ± 2 (1-21) 
12 
111 
39 --+ 4 (21-57) 0.03 
56 --+ 11 (I7-136) 0.03 
5 -+ 1 (i.5-14.4) NS 
39 _+ 4 (0.175-96) <0.0001 
43 _+ 20 (2-256) 
* Values expressed as mean +_ SEM (range). 
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DISCUSSION 
We previously reported a lack of correlation be- 
tween serum HCV RNA and ALT levels in chronic 
hepatitis C patients in a longitudinal study (23). In 
that study, serum HCV RNA level was quantitated 
using a semiquantitative assay (end-point dilution 
RT-PCR assay) that had a 10-fold interassay variabil- 
ity. Considerable controversy exists in the published 
literature regarding the relationship between levels of 
hepatitis C viremia and biochemical/histological ac- 
tivity of liver disease in patients with chronic HCV 
infection (2-6, 23). This is in part related to the poor 
standardization and interassay variability in amplifi- 
cation efficiency of RT-PCR assays. In this study, 
multiple samples [5-13 (mean 9 -+- 0.5)], at close 
intervals were tested for serum HCV RNA levels 
using a more consistent quantitative assay that relies 
on amplification of enzyme signal rather than nucleic 
acids. We confirmed our previous finding that except 
during interferon treatment, there was no correlation 
between serum HCV RNA and ALT levels in both 
immunocompetent and immunosuppressed patients 
with chronic HCV infection. This suggests that HCV- 
induced liver injury is not a direct result of the cyto- 
pathic effects of the virus. Further support against 
cytopathic liver injury is evidenced by the paradoxical 
increase in serum HCV RNA and decrease in ALT 
levels and the milder histological changes in renal 
transplant recipients receiving immunosuppressive 
therapy. In addition, while the renal transplant recip- 
ients had fivefoid greater variations in serum HCV 
RNA levels compared to the untreated immunocom- 
petent patients, the variations in ALT levels were 
similar. 
In accordance with other investigators, we found 
significant (up to 14-fold) variations in ALT levels 
during the course of chronic HCV infection (32, 33). 
Significant variations including intermittent disap- 
pearance in serum HCV RNA levels were also ob- 
served in the untreated patients. Intermittent loss of 
viremia has also been reported by other investigators 
using more sensitive RT-PCR assays (32, 33). The 
variability in serum HCV RNA and ALT levels may 
reflect fluctuations in the balance between host im- 
mune response and level of HCV replication and/or 
emergence of new versus changes in the proportion of 
existing viral quasispecies. 
In summary, we found that there was no correlation 
between serum HCV RNA and ALT levels during the 
natural course of chronic HCV infection. Immuno- 
suppression resulted in significantly higher serum 
HCV RNA but significantly lower ALT levels. 
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